Drawing for THIOLOGICS

USPTO serial 79115013

THIOLOGICS

Reviewed by CopyMark Law Group

Reg. 4452854Status 404
Filing date
Status date
Registration date
Dec 24, 2013
Examiner
TWOHIG, SHANNON MARIE
Law office
TMO LAW OFFICE 121

What this means

This page summarizes the public USPTO record for this serial number, including owners, goods and services, and prosecution history.

Need help with THIOLOGICS?

If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.

Current trademark owner
Monitor this mark, or talk with CopyMark about this registration.
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.

Owner

Attorney of record

The USPTO lists this attorney as the applicant's representative for correspondence on this application.

Joel D. Voelzke

Joel D. Voelzke IP Law Offices of Joel Voelzke, APC24772 W. Saddle Peak RoadMalibu, CA 90265UNITED STATES

Goods and services

ClassDescriptionStatusFirst use
001Chemicals for use in bioconjugation, reversible bioconjugation, irreversible bioconjugation, reversible cysteine protection, surface modification, and prodrug production; biochemicals, namely, polypeptides, polypeptides for in vivo applications, polypeptides for in vitro applications, polynucleic acids, polynucleic acids for in vivo applications, and polynucleic acids for in vitro applications; biomolecules, namely, proteins, peptides, antibodies, antibody fragments, antibody mimetic proteins, and polynucleic acids; chemical products for diagnostic use, namely, conjugates of polypeptides with small molecule drugs, imaging agents, and radionuclides for medical applications; biochemical preparations, namely, polypeptides, polynucleic acids, and antibodies, all for use in medical research; biochemical preparations, namely, polypeptides, polynucleic acids, and antibodies, all for use in diagnosis and treatment of diseaseSECTION 71 - CANCELLED—
005Pharmaceutical preparations, namely, polypeptide bioconjugates and polynucleic acid bioconjugates for use in diagnosis and treatment of autoimmune, cardiovascular, central nervous system, dental, dermatology, endocrine, gastrointestinal, genetic, hematology, immunological, infectious, inflammatory, menopausal, metabolic, musculoskeletal, neurological, oncology, ophthalmological, otolaryngology, psychiatric, respiratory, urogenital, urological and viral diseases and disorders in animals and humans; biological preparations, namely, polypeptide bioconjugates and polynucleic acid bioconjugates for use in diagnosis and treatment of autoimmune, cardiovascular, central nervous system, dental, dermatology, endocrine, gastrointestinal, genetic, hematology, immunological, infectious, inflammatory, menopausal, metabolic, musculoskeletal, neurological, oncology, ophthalmological, otolaryngology, psychiatric, respiratory, urogenital, urological and viral diseases and disorders in animals and humans; diagnostic preparations for medical purposes; diagnostic preparations for scientific or research use; diagnostic kits consisting primarily of antibody preparations, namely, antibody bioconjugates, namely, antibody-drug conjugates, antibody-radionuclide conjugates and antibody-imaging agent conjugates for use in diagnosis and treatment of autoimmune, cardiovascular, central nervous system, dental, dermatology, endocrine, gastrointestinal, genetic, hematology, immunological, infectious, inflammatory, menopausal, metabolic, musculoskeletal, neurological, oncology, ophthalmological, otolaryngology, psychiatric, respiratory, urogenital, urological and viral diseases and disorders in animals and humans; diagnostic kits consisting primarily of chemical products for medical diagnostic use, namely, polypeptide bioconjugates and polynucleic acid bioconjugates for use in diagnosis and treatment of autoimmune, cardiovascular, central nervous system, dental, dermatology, endocrine, gastrointestinal, genetic, hematology, immunological, infectious, inflammatory, menopausal, metabolic, musculoskeletal, neurological, oncology, ophthalmological, otolaryngology, psychiatric, respiratory, urogenital, urological and viral diseases and disorders in animals and humans; diagnostic kits consisting primarily of biochemical preparations, namely, polypeptide bioconjugates and polynucleic acid bioconjugates for use in diagnosis and treatment of autoimmune, cardiovascular, central nervous system, dental, dermatology, endocrine, gastrointestinal, genetic, hematology, immunological, infectious, inflammatory, menopausal, metabolic, musculoskeletal, neurological, oncology, ophthalmological, otolaryngology, psychiatric, respiratory, urogenital, urological and viral diseases and disorders in animals and humansSECTION 71 - CANCELLED—
042Scientific and technological services, namely, design and assembly of polypeptide bioconjugates and polynucleic acid bioconjugates, and design and optimization of proprietary bioconjugation technologies; biological research; chemical research and analysis; scientific advisory services relating to research and development in the field of diagnostic preparations and diagnostic products; providing scientific information and advisory services in the fields of scientific research and design, and biological and chemical researchSECTION 71 - CANCELLED—

Related trademarks

CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.

Prosecution history

DateCodeEventWhat it means
Aug 21, 2022DENCNOTIFICATION OF EFFECT OF CANCELLATION OF INTL REG E-MAILED—
Aug 21, 2022DETHDEATH OF INTERNATIONAL REGISTRATION—
Jan 29, 2022INNTTOTAL INVALIDATION PROCESSED BY THE IB—
Dec 23, 2021INTSTOTAL INVALIDATION OF REG EXT PROTECTION SENT TO IB—
Dec 23, 2021INPCINVALIDATION PROCESSED—
Oct 26, 2021INTRTOTAL INVALIDATION OF REG EXT PROTECTION CREATED—
Oct 2, 2021NREPNEW REPRESENTATIVE AT IB RECEIVED—
Feb 26, 2021C71TCANCELLED SECTION 71—
Dec 24, 2018REM3COURTESY REMINDER - SEC. 71 (6-YR) E-MAILED—
Jun 6, 2014FINOFINAL DECISION TRANSACTION PROCESSED BY IB—
May 19, 2014FICSFINAL DISPOSITION NOTICE SENT TO IB—
May 19, 2014FIMPFINAL DISPOSITION PROCESSED—
Mar 24, 2014FICRFINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB—
Dec 24, 2013R.PRREGISTERED-PRINCIPAL REGISTERYour trademark is registered on the Principal Register — the strongest form of federal trademark protection. You may use the ® symbol for the covered goods and services. Maintenance filings (Section 8 and renewals) are required to keep the registration alive.
Oct 8, 2013NPUBOFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED—
Oct 8, 2013PUBOPUBLISHED FOR OPPOSITIONYour mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance.
Oct 7, 2013GPNXNOTIFICATION PROCESSED BY IB—
Sep 18, 2013OPNSNOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB—
Sep 18, 2013OP2RNOTICE OF START OF OPPOSITION PERIOD CREATED, TO BE SENT TO IB—
Sep 18, 2013NONPNOTIFICATION OF NOTICE OF PUBLICATION E-MAILED—
Aug 30, 2013PREVLAW OFFICE PUBLICATION REVIEW COMPLETED—
Aug 22, 2013CNSAAPPROVED FOR PUB - PRINCIPAL REGISTER—
Aug 20, 2013TEMETEAS/EMAIL CORRESPONDENCE ENTERED—
Aug 20, 2013CRFACORRESPONDENCE RECEIVED IN LAW OFFICE—
Aug 20, 2013ERFRTEAS REQUEST FOR RECONSIDERATION RECEIVED—
Mar 7, 2013GNFNNOTIFICATION OF FINAL REFUSAL EMAILED—
Mar 7, 2013GNFRFINAL REFUSAL E-MAILEDA final Office Action (final refusal) means the examining attorney is maintaining at least one refusal and your options are narrower. You can file a response addressing the refusal, appeal to the Trademark Trial and Appeal Board, or let the application abandon.
Mar 7, 2013CNFRFINAL REFUSAL WRITTENA final Office Action (final refusal) means the examining attorney is maintaining at least one refusal and your options are narrower. You can file a response addressing the refusal, appeal to the Trademark Trial and Appeal Board, or let the application abandon.
Feb 14, 2013TEMETEAS/EMAIL CORRESPONDENCE ENTERED—
Feb 14, 2013CRFACORRESPONDENCE RECEIVED IN LAW OFFICE—
Feb 7, 2013ALIEASSIGNED TO LIE—
Feb 6, 2013TROATEAS RESPONSE TO OFFICE ACTION RECEIVEDThis event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action.
Aug 30, 2012RFNTREFUSAL PROCESSED BY IB—
Aug 7, 2012RFCSNON-FINAL ACTION MAILED - REFUSAL SENT TO IB—
Aug 7, 2012RFRRREFUSAL PROCESSED BY MPU—
Aug 7, 2012RFCRNON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW—
Aug 7, 2012MAFRAPPLICATION FILING RECEIPT MAILED—
Aug 6, 2012CNRTNON-FINAL ACTION WRITTENA non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application.
Aug 3, 2012DOCKASSIGNED TO EXAMINER—
Aug 3, 2012NWOSNEW APPLICATION OFFICE SUPPLIED DATA ENTERED—
Aug 2, 2012REPRSN ASSIGNED FOR SECT 66A APPL FROM IB—

Frequently asked questions

Related guidance